The other type of Co-working at BioPark

Everyone is talking about co-working at the moment. According to Wikipedia it stands for development in the field of “new work styles”. Freelancers, artists, start-ups and even digital nomads work concurrently in mostly large, open spaces and can profit from each other in this way. “Co-working spaces” make working spaces and infrastructure available (network, equipment, conference rooms) for a specified time period and facilitate the formation of a community. In the laboratory field co-working at the university has been standard within certain limits for quite a while. In the commercial sector this is often not possible because of certification and quality management. For this reason the trend in BioParks is rather towards small, closed rental entities rather than co-working spaces, which is very cost intensive.

 

An alternative to this can be the accommodation of two companies in one lease entity, which for example 2bind GmbH and the Assay.Works GmbH have succeeded in doing at BioPark Regensburg. As a small company with 2bind as an analysis service provider was on the lookout for laboratory premises. As there were not any suitable small premises available,  BioPark CEO Dr. Thomas Diefenthal brought the expanding young company together with the company Assay.Works, which as a small enterprise has just taken on large laboratory space for high-throughput screening in the biotechnology and pharmaceutical industry. In addition to the sublease contract both companies now have sealed a reciprocal service provider contract and thereby been able to considerably increase what they have to offer to pharma and biotech clients in the field of researching medicines. In the agreement there is also the common usage of the laboratory and office spaces at BioPark Regensburg. This promotes the seamless cooperation, scientific exchange and leads to acquisition of efficiency through the shared usage of the infrastructure and laboratory facilities.

 

The contract gives Assay.Works access to the comprehensive experience of 2bind with its various biophysical analysis services with molecular interaction studies, which are important for the identification, validation and characterization of potential active substances. In reciprocation clients can profit from 2bind from the wide spectrum of cell-based and biochemical testing processes and the automated high-throughput screening from Assay.Works. On this matter Dr. Ralf Schwandner, founder and CEO of Assay.Works says: “We look forward to working together with 2bind and to being able to offer our clients further biophysical assays for the characterization of hit and lead structures”. To this added Dr. Thomas Schubert, CEO of 2bind: “Such excellent opportunities simply must be seized when they are created. Assay.Works are proven experts in assay development and in HTS, which support early phase development of medicines.”